Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPOPL divergent transcript (SPOPL-DT) is a long non-coding RNA (lncRNA) located on chromosome 2q22.1, overlapping or adjacent to the SPOPL gene locus. Divergent transcripts are a class of noncoding RNAs generated through transcription starting from gene promoter regions in the opposite orientation to the coding gene, often resulting in short, unstable or regulatory RNAs. While some divergent lncRNAs have regulatory functions, such as modulating chromatin states or influencing the transcription of nearby genes, no specific functional or disease-related role has been defined for SPOPL-DT in the current literature. There are no known drug interactions, therapeutic mechanisms, or established biomarker roles for this transcript. Its inclusion as a drug target is likely inaccurate, as it is not a protein or conventional pharmacological target.
Not applicable; as it is not a known therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SPOPL divergent transcript (SPOPL-DT).